CHANGING THE WORLD BILLIONS OF CELLS AT A TIME

WIPO WIPO 2019

Schützen Sie diese Marke vor Nachahmern!

Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.

Die Internationale Marke CHANGING THE WORLD BILLIONS OF CELLS AT A TIME wurde als Wortmarke am 12.08.2019 bei der Weltorganisation für geistiges Eigentum angemeldet.

Markendetails Letztes Update: 15. September 2022

Markenform Wortmarke
Aktenzeichen 1513190
Länder Australien Kanada China Europäische Gemeinschaft Großbritannien Südkorea
Basismarke US Nr. 88320219, 28. Februar 2019
Anmeldedatum 12. August 2019
Ablaufdatum 12. August 2029

Markeninhaber

Paasheuvelweg 25A
1105 BP Amsterdam
NL

Waren und Dienstleistungen

05 Pharmaceutical preparations for the treatment of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; stem cells for medical purposes; living cells for medical use; biological preparations for the treatment of cancer; therapeutic pharmaceuticals utilizing neural crest cells for use in the treatment of cancer, autoimmune disease and infectious diseases; cell preparations, cellular vaccines and cellular biologics for the treatment of cancer and infectious diseases by autologous cell-based immunotherapy
42 Scientific and technological services, namely, scientific research, design, analysis and testing in the field of cancer evolution and new cancer therapies using natural killer cells; industrial research in the field of new pharmaceutical products and new cancer therapies; medical and veterinary research services in the nature of the manipulation of cells within a laboratory or research facility to enable natural killer cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services; conducting research and clinical trials for others relating to the use and the engineering of natural killer cells and cancer treatment and therapy; medical and scientific research in the field of cancer treatment and diagnosis; data collection for others for research purposes, namely, the collection, testing and research of patient molecular and genomic data (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Common Regulations); collection and preservation of human and animal DNA for research purposes; providing a website featuring health and healthcare information related to cancer research (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Common Regulations)
44 Medical testing for diagnostic or treatment purposes in the field of cancer research; medical diagnostic testing, monitoring and reporting services; medical evaluation of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; medical monitoring services; medical diagnostic, prognostic and theranostic screening and testing services; collection and preservation of DNA for medical purposes; consulting services in the nature of providing medical information; consulting services in the field of healthcare and cancer diagnoses; providing a website featuring health and healthcare information related to cancer, testing and screening (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Common Regulations); genetic testing for medical purposes; providing information in the field of cancer prevention, screening, diagnosis and treatment for medical diagnostic and treatment purposes; providing genetics assessments in the nature of genetic counseling; genetic testing for medical diagnostic purposes; genomic testing for medical diagnostic purposes; gene analysis and sequencing and DNA analysis and sequencing for medical diagnostic purposes and veterinary diagnostics purposes; gene analysis and sequencing and DNA analysis and sequencing for use in cancer diagnosis and treatment
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen

Markenhistorie

Datum Belegnummer Bereich Eintrag
24. August 2022 2022/37 Gaz US RAW: Partial Ceasing Effect
08. März 2022 2022/11 Gaz CA Ablehnung
03. November 2021 2022/7 Gaz AU RAW: Rule 18ter(2)(ii) GP following a provisional refusal
19. August 2021 2022/12 Gaz JP RAW: Second Part Fee Not Paid
19. August 2021 2021/34 Gaz JP RAW: Rule 18ter(2)(ii) GP following a provisional refusal
05. Juli 2021 2021/27 Gaz KR Ablehnung
15. Juni 2021 2021/28 Gaz SG Ablehnung
26. Mai 2021 2021/22 Gaz CA Ablehnung
25. März 2021 2021/12 Gaz JP Ablehnung
09. März 2021 2021/11 Gaz SG RAW: Refusal Transfer of Ownership
27. Januar 2021 2021/5 Gaz KR Ablehnung
26. Juni 2020 2020/27 Gaz EM Ablehnung
28. Mai 2020 2020/23 Gaz CN Ablehnung
22. Mai 2020 2020/22 Gaz AU Ablehnung
19. März 2020 2020/12 Gaz SG Ablehnung
15. Februar 2020 2020/8 Gaz GB Ablehnung
12. August 2019 2020/4 Gaz US Eintragung

ID: 141513190